1. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Issue 9 (September 2021) Authors: Reich, Daniel S; Arnold, Douglas L; Vermersch, Patrick; Bar-Or, Amit; Fox, Robert J; Matta, Andre; Turner, Timothy; Wallström, Erik; Zhang, Xinyan; Mareš, Miroslav; Khabirov, Farit A; Traboulsee, Anthony; Grand'Maison, Francois; Jacques, Francois; Traboulsee, Anthony; Tyblova, Michaela; Meluzinov... Journal: Lancet neurology Issue: Volume 20:Issue 9(2021) Page Start: 729 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗